Purpose of Review <p>Advancements in the management of bone and joint infections (BJIs) aim to improve outcomes while challenging long-standing treatment practices. This review discusses key updates, including use of oral antibiotics, shorter treatment durations, and novel approaches like phage therapy, as well as common clinical dilemmas, such as the role of rifampin.</p> Recent Findings <p>Recent studies reinforce the benefits of oral antibiotics, as well as shorter durations of therapy in BJIs with supporting evidence. Long-acting lipoglycopeptides offer an alternative to traditional IV antibiotic courses, and emerging evidence establishes a role for phage therapy in difficult-to-treat infections. Studies evaluating use of rifampin in prosthetic joint infections have produced conflicting results, necessitating a risk–benefit analysis prior to use. Additional data is needed to elucidate the role of rifampin in diabetes-related foot osteomyelitis.</p> Summary <p>Emerging therapeutic approaches are set to challenge conventional management practices in BJIs. Emphasis should be placed on integrating these approaches through antimicrobial stewardship initiatives.</p>